CDx(동반진단) 개발 시장 : 전략적 인사이트와 예측(2026-2035년)

The CDx Development Market is expected to increase at a CAGR of 13.2% from a market value of USD 1.86 billion in 2026 to USD 5.71 billion in 2035.

The biomarker validation services market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the growing complexity of biomarker-driven drug development, and the increasing regulatory emphasis on robust analytical and clinical validation. The market's evolution is characterized by the recognition that establishing analytical accuracy, reproducibility, and clinical relevance is essential before biomarkers can be applied in clinical trials or routine patient management. The convergence of advanced molecular technologies, including next-generation sequencing, multi-omics platforms, and liquid biopsy, is increasing assay complexity and driving demand for specialized validation services. Pharmaceutical and biotechnology companies are expanding biomarker-guided clinical trials across oncology, neurology, immunology, and cardiovascular diseases because treatment decisions increasingly depend on molecular signatures rather than disease classification alone. Regulatory agencies are strengthening biomarker qualification frameworks, increasing the importance of standardized validation protocols throughout clinical development. The market is witnessing significant investment in integrated bioanalytical and regulatory validation capabilities, positioning biomarker validation services as a critical enabler of precision medicine and companion diagnostic development.

Market Drivers

• The expansion of precision medicine clinical development represents the primary driver for the biomarker validation services market. Precision medicine increasingly defines modern pharmaceutical development because therapeutic efficacy depends on identifying responsive patient populations through validated biomarkers. Pharmaceutical sponsors are expanding biomarker-guided clinical trials across oncology, immunology, and neurology, creating greater demand for analytical and clinical validation services. Laboratory service providers are strengthening molecular testing infrastructure to accommodate increasingly complex validation requirements, which supports broader adoption of biomarker-driven development strategies, resulting in sustained growth in biomarker validation service utilization. The growth of companion diagnostic development is further accelerating market expansion through synchronized therapeutic and diagnostic validation. Companion diagnostics establish patient eligibility for targeted therapies and therefore require rigorous analytical validation before regulatory approval. Drug developers are integrating diagnostic development earlier within clinical programs to reduce regulatory uncertainty and improve treatment outcomes. Validation service providers are expanding integrated laboratory and regulatory capabilities because synchronized therapeutic and diagnostic submissions require harmonized evidence generation. The increasing regulatory focus on biomarker qualification is strengthening demand for standardized validation protocols. Regulatory agencies establish structured qualification pathways that encourage standardized biomarker validation while maintaining scientific rigor. Sponsors are engaging regulators earlier during development because qualification programs reduce uncertainty regarding biomarker acceptance. This regulatory evolution strengthens demand for validation partners capable of generating reproducible analytical and clinical evidence suitable for global submissions. The adoption of multi-omics and advanced molecular technologies is increasing assay complexity and driving outsourcing to specialized validation organizations. Multi-omics platforms increase biological insight but simultaneously introduce analytical variability that requires extensive validation. Pharmaceutical companies are incorporating genomic, transcriptomic, proteomic, and metabolomic biomarkers into clinical research, increasing assay complexity.

Market Restraints

• High analytical complexity increases validation costs and extends development timelines for novel biomarker platforms. The complexity of multi-omics and advanced molecular technologies creates challenges for efficient validation. Limited global standardization across laboratories reduces assay comparability and complicates multicenter clinical validation studies. The lack of harmonized protocols creates challenges for consistent validation across different regions. Regulatory expectations continue evolving, increasing documentation requirements and delaying commercialization for inadequately validated biomarkers. The evolving regulatory landscape creates uncertainty for developers seeking to validate novel biomarkers. Data integration and interpretation challenges create additional complexity for multi-parameter biomarker validation.

Technology and Service Type Insights

• The technology landscape is characterized by the growing importance of integrated validation platforms combining analytical, bioanalytical, and clinical capabilities. Clinical validation services account for a significant share of market demand because regulatory approval increasingly depends on demonstrating that biomarkers reliably predict clinically meaningful outcomes. Pharmaceutical companies are expanding biomarker-guided clinical trials across oncology and rare diseases, increasing the need for statistically robust validation studies involving diverse patient populations. Validation providers are integrating biostatistics, laboratory operations, and regulatory documentation within unified service offerings because fragmented workflows extend development timelines. NGS is expanding comprehensive biomarker identification capabilities. PCR remains important for focused biomarker detection. Immunoassays continue supporting protein biomarker measurement. Mass spectrometry is gaining adoption for comprehensive proteomic and metabolomic profiling. The segment analysis reveals that oncology represents the largest therapeutic application because targeted therapies increasingly require biomarker-guided patient selection before treatment initiation. Drug developers are incorporating genomic sequencing, circulating tumor DNA analysis, protein biomarkers, and multiplex molecular diagnostics into clinical development programs, increasing assay complexity. Neurology is generating increasing validation requirements because disease progression remains difficult to measure through conventional clinical assessments alone. Clinical validation remains the most strategically important validation stage because analytical performance alone does not demonstrate clinical utility. Pharmaceutical companies represent the leading end-user segment, with biotechnology companies and CROs expanding biomarker utilization. The integration of AI is becoming increasingly important because AI increasingly supports biomarker prioritization by integrating molecular datasets, pathology images, and clinical outcomes. Validation laboratories are incorporating advanced computational workflows because sponsors require scalable analytical approaches capable of managing high-dimensional biological data.

Competitive and Strategic Outlook

• The competitive landscape features established clinical research organizations and laboratory service providers alongside specialized biomarker, regulatory, and analytical companies. IQVIA differentiates itself through its ability to combine global clinical research operations with advanced healthcare analytics and real-world evidence capabilities, enabling end-to-end biomarker validation throughout drug development. Labcorp Drug Development maintains a strong competitive position through its comprehensive central laboratory network and extensive biomarker testing capabilities supporting global clinical development, providing analytical validation, bioanalytical testing, molecular diagnostics, immunoassays, flow cytometry, histopathology, and companion diagnostic support. ICON distinguishes itself through its integrated clinical development platform that combines biomarker science, laboratory services, medical imaging, biostatistics, and regulatory consulting, supporting pharmaceutical, biotechnology, and medical device organizations. PAREXEL differentiates itself through its strong regulatory consulting capabilities combined with global clinical development expertise, enabling integrated biomarker validation throughout the drug development lifecycle. Syneos Health combines clinical development, commercialization, and consulting capabilities to support biomarker-driven drug development across multiple therapeutic areas. Companies are pursuing service portfolio expansion through innovation in multi-omics platforms, AI-enabled analytics, and integrated regulatory support. Strategic collaborations between service providers and pharmaceutical companies are increasing, driven by the need for integrated biomarker development. Recent key developments include CellCarta launching a consortium to accelerate platform-agnostic biomarker innovation across drug development, bringing together several AI pathology partners to support biopharma sponsors. Aptamer Group launched a biomarker discovery service built around its Optimer platform and proteomic analysis to identify and validate disease markers faster. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where pharmaceutical development activity is accelerating.

Short Conclusion

• The biomarker validation services market is positioned for sustained growth driven by the convergence of precision medicine, regulatory emphasis, and technological innovation. The transition from a supporting laboratory function into a core element of therapeutic development represents a fundamental shift in pharmaceutical R&D. While challenges related to analytical complexity, standardization, and regulatory evolution persist, strategic investments in technology, expertise, and integrated capabilities are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with biomarker validation services evolving into a critical enabler of precision medicine, supporting biomarker discovery, therapeutic development, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

CDx Development Market: Strategic Outlook and Growth Dynamics 2026-2035

• The global companion diagnostics development market is projected to grow from USD 1.86 billion in 2026 to USD 5.71 billion by 2035, at a CAGR of 13.2% during the forecast period.
• The companion diagnostics (CDx) development market is undergoing significant transformation driven by the paradigm shift toward precision medicine, the increasing regulatory emphasis on biomarker-guided therapies, and the growing complexity of targeted therapeutic development. The market's evolution is characterized by the recognition that synchronized development of therapeutics and diagnostics is essential for optimizing patient selection, improving clinical trial efficiency, and strengthening regulatory evidence. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and artificial intelligence, is enabling more comprehensive biomarker discovery and validation. Pharmaceutical companies are integrating diagnostics earlier during clinical development because biomarker-guided trial enrollment improves response rates and strengthens regulatory evidence packages. Regulatory agencies are strengthening companion diagnostic requirements as precision medicine approvals increasingly depend on validated patient selection strategies. The market is witnessing significant investment in integrated drug-diagnostic co-development, multi-omics platforms, and AI-enabled interpretation tools, positioning CDx development as a critical enabler of precision medicine across global healthcare systems.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global CDx Development Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Companion Diagnostics Industry Overview
• 3.3 Evolution of the CDx Development Ecosystem
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Precision Medicine Landscape
• 3.8 Biomarker Discovery and Validation Overview
• 3.9 Drug-Diagnostic Co-development Landscape
• 3.10 Companion Diagnostic Development Workflow
• 3.11 Regulatory Co-development Framework
• 3.12 Clinical Development and Validation Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in CDx Development
• 6.2 Biomarker Innovation Trends
• 6.3 Next-Generation Sequencing (NGS) Integration
• 6.4 Artificial Intelligence in Companion Diagnostic Development
• 6.5 Digital Pathology and Multi-omics Integration
• 6.6 Clinical Trial Analysis
• 6.7 Companion Diagnostic Pipeline Analysis
• 6.8 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global CDx Development Market Landscape Analysis

• 8.1 Analysis by Development Stage
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Technology Platform
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Therapeutic Area
• 8.6 Analysis by End User

9. Global CDx Development Market Segment Analysis (2021-2035)

• 9.1 By Development Stage
  • 9.1.1 Discovery Stage
  • 9.1.2 Preclinical Development
  • 9.1.3 Clinical Development
  • 9.1.4 Regulatory Approval Stage
  • 9.1.5 Post-commercialization
• 9.2 By Technology Platform
  • 9.2.1 Polymerase Chain Reaction (PCR)
  • 9.2.2 Next-Generation Sequencing (NGS)
  • 9.2.3 Immunohistochemistry (IHC)
  • 9.2.4 In Situ Hybridization (ISH)
  • 9.2.5 Other Molecular Technologies
• 9.3 By Biomarker Type
  • 9.3.1 Genomic Biomarkers
  • 9.3.2 Proteomic Biomarkers
  • 9.3.3 Transcriptomic Biomarkers
  • 9.3.4 Others
• 9.4 By Sample Type
  • 9.4.1 Tissue
  • 9.4.2 Blood (Liquid Biopsy)
  • 9.4.3 Other Biological Samples
• 9.5 By Therapeutic Area
  • 9.5.1 Oncology
  • 9.5.2 Neurology
  • 9.5.3 Infectious Diseases
  • 9.5.4 Autoimmune Diseases
  • 9.5.5 Cardiovascular Diseases
  • 9.5.6 Other Therapeutic Areas
• 9.6 By End User
  • 9.6.1 Pharmaceutical & Biotechnology Companies
  • 9.6.2 Companion Diagnostic Developers
  • 9.6.3 Contract Research Organizations (CROs)
  • 9.6.4 Others

10. Global CDx Development Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global CDx Development Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Agilent Technologies, Inc.
• 13.3 QIAGEN N.V.
• 13.4 Thermo Fisher Scientific Inc.
• 13.5 Illumina, Inc.
• 13.6 BioMerieux
• 13.7 Exact Sciences
• 13.8 Guardant Health, Inc.
• 13.9 Foundation Medicine, Inc.
• 13.10 Abbott Laboratories

14. Global CDx Development Market Commercial Forecast Analysis

• 14.1 By Technology Platform
• 14.2 By Development Phase
• 14.3 By Therapeutic Area
• 14.4 By Biomarker Type
• 14.5 By End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends